Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIO-8221 in Advanced Solid Tumors
NCT07300943Phase 2Recruiting
- Sponsor
- Callio Therapeutics
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of CLIO-8221 in solid tumor (advanced stage), sponsored by Callio Therapeutics. Primary endpoints: Adverse Events, Laboratory Abnormalities and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
CLIO-8221
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07300943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300943.